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Rosuvastatin Affecting Aortic Valve
Endothelium to Slow the Progression of Aortic Stenosis
Luis M. Moura, MD,*† Sandra F. Ramos, MSC,‡ José L. Zamorano, MD, PHD,†
Isabel M. Barros, MD,* Luis F. Azevedo, MD,‡ Francisco Rocha-Gonçalves, MD, PHD,‡
Nalini M. Rajamannan, MD§
Matosinhos and Oporto, Portugal; Madrid, Spain; and Chicago, Illinois
Objectives The objective of this study was to test the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reduc-
tase inhibitor on the progression of moderate to severe aortic stenosis as measured by echocardiography.
Background Recent retrospective studies support the hypothesis that statins slow the progression of aortic stenosis.
Methods We performed an open-label, prospective study evaluating 121 consecutive patients with asymptomatic moderate to
severe aortic stenosis (aortic valve area 1.0 cm2; mean age 73.7  8.9 years; 57 men and 64 women), treated
with and without rosuvastatin according to the National Cholesterol Education Program Adult Treatment Panel III
guidelines. Echocardiographic, serum lipid, and inflammatory markers were measured at baseline and every 6
months for 18 months.
Results Sixty-one patients (50.4%) with elevated LDL (159.7 33.4 mg/dl), aortic valve velocity (3.65 0.64 m/s), and aor-
tic valve area (1.23  0.42 cm2) received rosuvastatin (20 mg/day), and 60 (49.6%) with a normal LDL (118.6
37.4 mg/dl), aortic valve velocity (3.62 0.61 m/s), and aortic valve area (1.20 0.35 cm2) received no statin. Dur-
ing a mean follow-up of 73  24 weeks, the change in aortic valve area in the control group was0.10  0.09
cm2/year versus 0.05  0.12 cm2/year in the rosuvastatin group (p 0.041). The increase in aortic valve velocity
was 0.24  0.30 m/s/year in the control group and 0.04 0.38 m/s/year in the rosuvastatin group (p 0.007).
There was significant improvement in serum lipid and echocardiographic measures of aortic stenosis in the statin
group.
Conclusions Prospective treatment of aortic stenosis with rosuvastatin by targeting serum LDL slowed the hemodynamic pro-
gression of aortic stenosis. This is the first prospective study that shows a positive effect of statin therapy for this
disease process. (Rosuvastatin Affecting Aortic Valve Endothelium; http://www.clinicaltrials.gov/ct/show/
NCT00114491?order  1; NCT0014491). (J Am Coll Cardiol 2007;49:554–61) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.072r
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Calcific aortic stenosis is the most common
indication for surgical valve replacement (1).
The number of valve replacements is increasing
because of the aging population (2). Currently,
the only established therapy for patients with
severe symptomatic aortic stenosis is surgical
alve replacement (3,4). In 1997, Stewart et al. (5) defined
he independent risk factors associated with calcific aortic
tenosis from the Cardiovascular Health Study, which in-
lude: elevated lipoprotein (a), low-density lipoprotein (LDL)
holesterol, hypertension, male gender, and smoking. These
rom the *Hospital Pedro Hispano, Matosinhos, Portugal; †Hospital Clinico
niversitário S. Carlos, Madrid, Spain; ‡Oporto University Medical School, Oporto,
ortugal; and §Northwestern University Feinberg School of Medicine, Chicago,
llinois. Dr. Rajamannan is an inventor on the patent for the use of statins in aortic
alve disease. She does not receive any financial royalties from this patent.z
Manuscript received April 19, 2006; revised manuscript received July 20, 2006,
ccepted July 23, 2006.isk factors are similar to the risk factors defined for coronary
eart disease by the Framingham Heart Study, and have been
alidated in other aortic stenosis risk factor databases (6–10).
Until recently, the mechanism of degenerative aortic stenosis
as thought to be caused by a passive accumulation of calcium
long the surface of the aortic valve leaflet. However, there are
growing number of experimental studies showing that aortic
alve calcification is an active biological process that can
e targeted with medical therapy such as statins (11–13).
See page 562
ecently, this hypothesis has been confirmed with an increas-
ng number of retrospective studies showing the effects of
tatins and angiotensin-converting enzyme inhibitors in slow-
ng the progression of aortic valve stenosis (6,14–18).
We hypothesized that 3-hydroxy-3-methylglutaryl coen-
yme A (HMG CoA) reductase inhibitors may slow the
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February 6, 2007:554–61 Statins in Aortic Valve Diseaseemodynamic progression of calcific aortic stenosis and im-
rove inflammatory markers that have been described clinically
o affect the aortic valve endothelium (19–21). To test this
ypothesis we examined the effects of rosuvastatin in an
pen-label prospective study to determine whether an HMG
oA reductase inhibitor can slow the progression of moderate
o severe aortic stenosis as defined by echocardiographic
arameters (21–24). We treated a population of patients with
levated cholesterol levels and moderate to severe aortic steno-
is and measured the hemodynamic progression by echocardi-
graphy (25). We also monitored serum LDL cholesterol in
hese patients to determine whether rosuvastatin can slow the
rogression of aortic stenosis using a targeted therapeutic
pproach.
ethods
e performed an open-label, prospective study on patients
ho have moderate to severe aortic stenosis as defined by an
ortic valve area between 1.0 and 1.5 cm2. We treated 121
atients presenting consecutively with asymptomatic aortic
Baseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Characteristic
All Patients
(n  121)
Clinical
Age (yrs) 73.7 8.9
Men, n (%) 57 (47.1)
Arterial hypertension, n (%) 77 (63.6)
Diabetes, n (%) 39 (32.2)
Smokers, n (%) 4 (3.3)
Sinus rhythm, n (%) 106 (87.6)
Diastolic blood pressure (mm Hg) 75.9 12.9
Systolic blood pressure (mm Hg) 150.6 22.9
Cardiac frequency (beats/min) 72.8 13.0
Laboratory analysis
Total cholesterol level (mg/dl) 217.7 50.1
HDL (mg/dl) 54.0 12.7
LDL (mg/dl) 137.5 39.6
TG (mg/dl) 133.6 89.4
SAA (mg/dl) 0.6 (0.4–1.0)
IL-6 (pg/ml) 12.7 (9.5–18.0)
TNF (pg/ml) 10.3 (5.7–15.6)
BNP (pg/ml) 40.0 (19.8–90.5)
hsCRP (mg/l) 2.5 (1.0–6.7)
sCD40L (ng/ml) 1.97 1.07
Echocardiographic
Peak jet velocity (m/s) 3.63 0.62
Peak gradient (mm Hg) 54.3 18.5
Mean gradient (mm Hg) 35.7 13.3
Aortic valve area (cm2) 1.21 0.38
LV diastolic (mm) 51.7 5.1
LV systolic (mm) 33.9 4.4
EF (%) 54.9 3.1
Data are presented as mean  SD when the variables are normally di
groups were based on an analysis of variance (ANOVA) for variables wi
p  0.05 for differences between groups.
BNP  brain natriuretic peptide; EF  ejection fraction; HDL 
interleukin; LDL low-density lipoprotein; LV left ventricular; SAA serum
tumor necrosis factor.tenosis to the cardiology clinic
n Hospital Pedro Hispano (age
3.7  8.9 years; 57 men, 64
omen) with and without rosu-
astatin according to the Na-
ional Cholesterol Education
rogram Adult Treatment Panel
II (NCEP-ATPIII) guidelines.
atients with elevated LDL
130 mg/dl received rosuva-
tatin and those with LDL130
g/dl did not receive the ther-
py. Echocardiographic and se-
um markers for high-sensitivity C-reactive protein
hsCRP), interleukin (IL)-6, and CD40 were measured at
aseline and every 6 months for 18 months. Table 1 shows
he baseline clinical characteristics in of all the patients
nrolled.
At study entry, the following clinical data were col-
ected: age, gender, history of smoking, hypercholester-
tatin-Treated Group
(n  61)
Untreated Group
(n  60) p Value
73.4 8.5 73.9 9.4 0.749
21 (34.4) 36 (60.0) 0.006
45 (73.8) 32 (53.3) 0.024
26 (42.6) 13 (21.7) 0.019
0 (0) 4 (6.7) 0.057
56 (91.8) 50 (83.3) 0.179
78.4 13.6 73.4 13.6 0.033
154.4 18.6 146.6 26.2 0.060
73.8 13.1 71.8 12.8 0.379
243.0 40.5 192.0 45.8 0.001
55.0 13.2 53.1 12.2 0.399
158.2 31.7 116.5 20.9 0.001
152.1 102.3 114.5 69.7 0.022
0.6 (0.3–0.8) 0.7 (0.4–0.8) 0.370
12.7 (9.4–18.0) 12.5 (9.8–19.1) 0.510
10.4 (7.0–13.4) 9.2 (5.7–17.0) 0.965
34.7 (15.5–83.4) 47.0 (24.6–91.6) 0.095
2.7 (1.0–6.8) 2.0 (1.0–5.1) 0.477
2.05 1.14 1.89 0.99 0.414
3.65 0.64 3.62 0.61 0.788
54.7 18.9 53.9 18.2 0.828
35.3 13.4 36.1 13.4 0.752
1.23 0.42 1.20 0.35 0.636
50.1 5.8 52.5 4.1 0.110
33.2 4.9 34.6 3.8 0.070
54.3 3.1 55.6 4.4 0.060
d and as mean (interquartile range) when non-Gaussian. Comparison
al distribution or on a Mann-Whitney test for non-Gaussian variables.
nsity lipoprotein; hsCRP  high-sensitivity C-reactive protein; IL 
Abbreviations
and Acronyms
ANOVA  analysis of
variance
HMG CoA  3-hydroxy-3-
methylglutaryl coenzyme A
hsCRP  high-sensitivity
C-reactive protein
IL  interleukin
LDL  low-density
lipoproteinS
stribute
th norm
high-de
amyloid A; sCD40L soluble CD40 ligand; TG triglycerides; TNF
o
p
m
p
m
a
c
d
p
b
o
o
s
e
m
d
e
t
s
p
o
p
t
e
d
l
2
s
i
A
i
t
f
o
p
P
a
o
t
h
i
s
i
u
t
d
o
m
E
t
c
I
l
t
556 Moura et al. JACC Vol. 49, No. 5, 2007
Statins in Aortic Valve Disease February 6, 2007:554–61lemia, diabetes mellitus, arterial hypertension (blood
ressure 140/90 mm Hg based on the average of repeated
easurements), or coronary artery disease (documented
revious myocardial infarction or angiographically docu-
ented coronary artery stenosis). There was no new initi-
tion of statin therapy in the untreated group during the
ourse of the study. No patients in the treatment group
iscontinued the statin treatment. Patients taking antihy-
ertensive medications such as calcium antagonists, beta-
lockers, and diuretics and as indicated on oral antidiabetics
r insulin for diabetes were included in this study. Patients
n angiotensin-converting enzyme inhibitors were excluded.
The 2 primary end points included progression of aortic
tenosis and improvement in LDL cholesterol. Secondary
Figure 1 Patient Flow Diagram
Flow chart of patient enrollment. pts  patients.
Changes in Hemodynamic Markers
Table 2 Changes in Hemodynamic Markers
Characteristic
Untreated Patie
Baseline Follow-U
Peak jet velocity (m/s) 3.56 0.56 3.86 0.
Peak gradient (mm Hg) 52.1 16.2 61.3 19
Mean gradient (mm Hg) 34.7 12.1 40.4 14
Aortic valve area (cm2) 1.24 0.35 1.11 0.
LV diastolic (mm) 52.6 4.2 53.9 2.
LV systolic (mm) 34.1 4.0 35.7 2.
EF (%) 55.9 4.7 57.9 3.
Data are presented as mean SD. Hemodynamic changes were asses
data.
Abbreviations as in Table 1.nd points were the improvement in the inflammatory
arkers. Patients excluded were those with coronary artery
isease as measured by clinical history, echocardiographic
vidence of rheumatic mitral valve disease, previous statin
herapy, congenital heart disease (bicuspid aortic valve),
ubaortic obstruction, creatinine 2.0 mg/dl (to avoid the
otential confounder of an elevated serum CaPO4), active
r chronic liver disease, mild aortic regurgitation, and
revious aortic valve surgery. These subjects were asymp-
omatic as defined by clinical history, without clinical
vidence of vascular, neoplastic, metabolic, or inflammatory
isease by careful clinical history, examination, and routine
aboratory tests. Institutional review board approval (IRB-
2352) from Hospital Pedro Hispano was obtained before
tudy initiation, and each study participant signed an
nformed consent before enrollment. Rosuvastatin (Crestor,
stra Zeneca, Wilmington, Delaware) was provided to the
nvestigators without any intellectual or financial contribu-
ion from Astra Zeneca. Figure 1 shows the flow diagram
rom the initial time of patient screening to the composition
f the final patient population. Trial registration was com-
leted (Clinical Trials Government Identifier NCT0014491).
atients on antihypertensive medications such as calcium
ntagonists, beta-blockers, and diuretics and as indicated on
ral antidiabetics or insulin for diabetes were included in
his study. Patients on angiotensin-converting enzyme in-
ibitors were excluded. In the untreated group there was no
nitiation of the statin therapy. None of the patients on
tatin therapy developed any adverse reactions to the med-
cation. There was 1 patient who developed symptoms and
nderwent aortic valve replacement. The cause of death in
he statin-treated group was sudden death, and the family
id not request an autopsy. In the nonstatin group the cause
f death in 2 patients was sepsis, and 2 patients had a
alignancy.
chocardiographic measurements. Comprehensive trans-
horacic echocardiograms were performed in a single echo-
ardiographic laboratory. Immediate physician review (level
II) allowed re-imaging for quality control. Standard Dopp-
er measurements of the left ventricular outflow tract and
he aortic valve from multiple windows to obtain the
Treated Patients
p Value Baseline Follow-Up p Value
0.001 3.64 0.65 3.73 0.74 0.112
0.001 54.3 19.1 57.7 22.3 0.072
0.001 34.9 13.7 39.1 16.6 0.004
0.001 1.22 0.40 1.16 0.42 0.010
0.005 50.1 7.1 53.7 5.0 0.001
0.008 33.2 5.3 35.1 3.3 0.010
0.017 53.5 3.6 58.0 3.4 0.001
paired t test. p 0.05 for differences between baseline and follow-upnts
p
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February 6, 2007:554–61 Statins in Aortic Valve Diseaseaximum velocity were recorded, and the mean gradient,
he peak velocity, and the aortic valve area were measured
nd calculated as defined by the American Heart Association/
merican College of Cardiology guidelines for the clinical
pplication of echocardiography (26). For assessment of
emodynamic progression, echocardiographic studies were
sed. The data were obtained by 2 observers (L.M. and I.B.)
ho were blinded to the treatments. We reported the mean
alue between the 2 echocardiographic readers. Reproduc-
bility of echocardiography was determined in a subset of 30
atients. Intraobserver and interobserver coefficients of re-
roducibility (27) were 0.22 cm2 and 0.18 cm2 for aortic
alve area, and 0.22 m/s and 0.16 m/s for aortic valve peak
elocity, respectively, between the 2 echocardiographic phy-
icians (L.M. and I.B.).
nflammatory markers. Patients fasted for 12 h and then
erum was obtained at the time of randomization and at 6,
2, and 18 months of follow-up, and serum was immedi-
tely centrifuged at 1,000 g at 4°C for 20 min. Plasma was
eparated into aliquots and shipped to a central laboratory,
here it was stored at 80°C for batch analysis.
aboratory tests. We analyzed plasma IL-6 (Cell Com,
eckman Coulter, Nyon, Switzerland), and soluble CD40
igand (sCD40L) (Biosource, Camarillo, California). The
sCRP (Dada Behring, New Castle, Delaware) levels were
easured by a high-sensitivity assay. All assays have re-
orted intra-assay and inter-assay coefficients of variation:
5% and 15%, respectively. In addition, lipid profiles,
erum creatinine levels, glucose, aldolase, creatine phos-
hokinase, aspartate transaminase, and alanine transaminase
ere assessed by standard methods in our laboratories, and
nnualized Changes in Hemodynamic Markers
Table 3 Annualized Changes in Hemodynamic Markers
Characteristic
Untreated
Patients
Treated
Patients p Value
Peak jet velocity (m/s/yr) 0.24 0.30 0.04 0.38 0.007
Aortic valve area (cm2/yr) 0.10 0.09 0.05 0.12 0.041
Peak gradient (mm Hg/yr) 7.57 9.62 2.13 12.91 0.010
Mean gradient (mm Hg/yr) 5.06 7.17 2.08 8.15 0.049
ata are presented as mean  SD. Treatment comparisons for hemodynamic variables were
ased on analysis of covariance analysis. p  0.05 for differences between groups.
Changes in Serum Markers
Table 4 Changes in Serum Markers
Characteristic
Untreated Patien
Baseline Follow-U
Total cholesterol (mg/dl) 193.7 47.9 195.1 3
LDL cholesterol (mg/dl) 118.6 37.4 117.8 2
TG (mg/dl) 116.2 71.1 116.7 6
hsCRP (mg/l) 2.4 (1.0–6.9) 1.9 (0.8–4
IL-6 (pg/ml) 12.5 (9.8–19.1) 2.9 (2.9–7
sCD40L 2.01 0.97 0.93 0
Data are presented asmean SDwhen the variables are normally dist
of follow-up data used a paired t test for variables with normal distribu
differences between groups.
Abbreviations as in Table 1.ll values were within normal limits from standard labora-
ory values (data not shown).
tatistical analysis. Patient characteristics are presented as
number (percentage) for categorical variables, as mean 
D when the variables are normally distributed or as median
ith interquartile ranges when non-Gaussian. To test the
ormality of continuous variables, we used the Kolmogorov-
mirnov test with Liliefors correction (parameters distribu-
ion unknown). Reproducibility was assessed by the method
f Bland and Altman (27), and expressed as the coefficient
f reproducibility (twice the SD of the differences). We used
he criteria for a normally distributed population to decide
etween the tests. Analysis of variance (ANOVA) and the
aired Student t test are parametric procedures used when
he population is normally distributed. The Mann-Whitney
test and Wilcoxon tests are the nonparametric alternative
ests for ANOVA and paired Student t test, respectively.
roup comparisons for continuous outcome variables were
nalyzed using ANOVA or Mann-Whitney U test. Com-
arisons of follow-up data used paired Student t test or
ilcoxon test as appropriate. Chi-square tests were used to
valuate differences in the categorical variables. Aortic
tenosis progression was determined by dividing the change
etween the final and baseline measurements by the dura-
ion of follow-up. Treatment comparisons for aortic stenosis
rogression variables were based on an analysis of covari-
nce. The variables/covariates used were LDL cholesterol,
ge, hypertension, diabetes, baseline aortic valve area, base-
ine peak jet velocity, and baseline peak and mean gradients.
he Pearson coefficient has been used to assess the linear
orrelation between the change in LDL cholesterol levels
nd aortic stenosis progression. Analyses were performed
sing SPSS software, version 12.0 (SPSS Inc., Chicago,
llinois). A two-tailed p value  0.05 was considered to
ndicate statistical significance.
esults
uring a mean follow-up of 73  24 weeks, the decrease in
ortic valve area in the nonstatin group was 0.10  0.09
m2/year versus 0.05  0.12 cm2/year in the statin
reatment group (p  0.041). The increase in peak aortic
Treated Patients
p Value Baseline Follow-Up p Value
0.830 245.5 41.7 175.4 31.6 0.001
0.882 159.7 33.4 93.3 21.1 0.001
0.945 153.9 107.8 124.0 57.8 0.003
0.363 2.7 (1.1–6.9) 2.3 (0.9–5.1) 0.030
0.001 12.7 (9.4–18.0) 2.9 (2.9–5.2) 0.001
0.001 2.36 1.04 1.06 0.93 0.001
and asmedian (interquartile range) when non-Gaussian. Comparisons
a Wilconxon test for non-normally distributed variables. p  0.05 forts
p
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Statins in Aortic Valve Disease February 6, 2007:554–61alve velocity in the nonstatin group was 0.24  0.30
/s/year versus 0.04  0.38 m/s/year (p  0.007) in the
tatin group. The progression in peak gradient over the
ollow-up period for the nonstatin group was 7.57  9.62
m Hg/year, and was 2.13  12.91 mm Hg/year (p 
.010) in the statin group. The change in mean gradient was
5.06  7.17 mm Hg/year in the nonstatin group versus
2.08 8.15 mm Hg/year in the statin group (p 0.049).
The primary end points in Table 2 show the numerical
alues for the hemodynamic parameters at baseline and at
he end of the study. Table 3 shows the comparison of the
nnual changes in the hemodynamic measurements in the 2
roups with statistical improvement in the peak jet velocity,
ortic valve area, peak gradient, and mean gradient. The
econdary end points are shown in Table 4. The treated
atients had improvement of all of the serum markers: total
holesterol, LDL cholesterol, triglycerides, hsCRP, IL-6
nd sCD40L. Figure 2 shows the comparison data for the
reated versus untreated groups at 0, 26, 52, and 78 weeks.
igures 2A, 2B, and 2C show the improvement in the peak
et velocity, mean gradient, and aortic valve area in the
reated versus untreated population. Figures 3A, 3B, and 3C
how a weak but statistically significant correlation of the
mprovement in peak jet velocity, mean gradient, and aortic
alve area with the change in LDL cholesterol levels.
iscussion
n the RAAVE (Rosuvastatin Affecting Aortic Valve Endo-
helium) study, we found a change in aortic valve area in the
ontrol group of 0.10  0.09 cm2 per year versus 0.05 
.12 cm2 per year in the rosuvastatin group (p  0.041). In
ddition, the increase in peak aortic valve velocity was0.24
.30 m/s/year in the control group as compared with0.04
.38 m/s/year in the rosuvastatin group (p  0.007). These
ata indicate that in this small prospective hypothesis-driven
tudy we found a slowing of progression of aortic valve disease
y echocardiography. Emerging epidemiologic and histologic
tudies have shown convincing clinical risk factor evidence
oward an inflammatory atherosclerotic hypothesis for the
ellular mechanism of aortic valve stenosis (5–9,28–31). Ga-
ante et al. (21) have shown a correlation with serum hsCRP
evels, a serum inflammatory marker, with the severity of aortic
alve stenosis. Furthermore, there are a growing number of in
ivo experimental models showing that experimental hyper-
holesterolemia induces an atherosclerotic valve lesion that
ecomes stenotic (11). These stenotic valves express bone
atrix markers and calcification markers that are attenuated
ith atorvastatin therapy (12,32,33). This clinical, epidemio-
ogic, and experimental evidence suggests that aortic valve
tenosis is an atherosclerotic process similar to vascular athero-
clerosis. Currently, there are 6 retrospective studies that
onsistently show that statin therapy is associated with slowing
f the hemodynamic progression of aortic stenosis (6,10,14–
7). Therefore, targeting this disease with medical therapy may
e an important therapeutic strategy in the future. aIn the RAAVE study, we treated patients who presented
ith asymptomatic aortic stenosis and elevated cholesterol
evels as defined by the NCEP-ATPIII guidelines. This
tudy shows that statins slow the primary end points of
emodynamic progression as measured by peak velocity,
Figure 2 Progression of Aortic Valve Stenosis in Patients Treated
With Rosuvastatin Therapy and Untreated Patients
(A) Aortic jet velocity in treated versus untreated patients. (B) Aortic mean gra-
dient in treated versus untreated patients. (C) Aortic valve area in treated ver-
sus untreated patients.ortic valve area, peak gradient, and mean gradient. Sec-
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February 6, 2007:554–61 Statins in Aortic Valve Diseasendary end points including CRP levels, IL-6, sCD40L,
nd serum LDL levels were all reduced significantly in the
Figure 3 Correlation of LDL Cholesterol With Echocardiographic
Hemodynamic Measurements in Treated Patients
(A) Aortic jet velocity in treated patients. (B) Aortic mean gradient in treated
patients. (C) Aortic valve area in treated patients. LDL  low-density
lipoprotein.osuvastatin-treated patients with moderate aortic stenosis. ehe RAAVE study confirms the data from Otto et al. (34),
hich indicate that the rate of hemodynamic progression in
prospective study of asymptomatic aortic stenosis can be
easured specifically by the rate of change in jet velocity
p  0.001). Our data also indicate that the patients in the
ntreated group with a lower risk factor profile in terms of
erum LDL have a lower inflammatory profile over the
ollow-up period. We hypothesize that if the biology of the
ortic valve is a bone differentiation process as described by
ohler et al. (35), and Rajamannan et al. (36), then as more
one forms and the valve calcifies there may be a decrease in
he inflammatory states that are present in the earlier aortic
alve lesion (37). A recent study by Sanchez et al. (38) has
lso shown lower levels of CRP in patients who had a slower
ate of progression. These inflammatory marker data are
nly observations and do not provide any confirmative direct
vidence of the biological disease activity in these patients.
The first prospective study testing statins in aortic valve
isease, by Cowell et al. (39), found that high-dose atorvastatin
id not slow the progression of aortic stenosis in this patient
opulation. The SALTIRE (Scottish Aortic Stenosis and
ipid Lowering Trial, Impact on Regression) study initiated
torvastatin in patients who had more advanced aortic stenosis
s defined by a mean aortic valve area of 1.03 cm2, as compared
ith the mean aortic valve area in the RAAVE study of 1.23
m2 at baseline before treatment with rosuvastatin. The
AAVE study tested an open-label hypothesis approach to
etermine whether statin therapy for elevated LDL is benefi-
ial earlier in the natural history of asymptomatic aortic
tenosis. The RAAVE study did not measure calcium scores,
o no comparison can be made in terms of this calcification
arker. However, the SALTIRE study’s initial patient popu-
ation had elevated calcium scores present in the aortic valves,
ndicating a heavy burden of valve calcification (35,36,40)
resent in the initial study population, which again correlates
ith the more severe aortic valve area at baseline in the
ALTIRE study as compared with the RAAVE study.
Rosenhek et al. (40) have previously shown that calcification
s an important marker for the severity and outcomes of
atients with aortic stenosis, therefore indicating that the large
urden of calcification in the aortic valve predicts a higher risk
or this patient population. We believe that the degree of aortic
tenosis will be the most beneficial in the sclerotic or milder
hase. We hypothesize that the treatment effect is probably
aused by lipid and non–lipid-lowering effects of the statins,
hich have been described in a retrospective clinical report (15)
nd experimental studies. Recent experimental studies have
hown that Lrp5, the LDL co-receptor, regulates calcification
n the aortic valve and aorta (41,42). Rajamannan et al. (33)
ave shown in experimental animal models the potential
on–lipid-lowering effects of statins in the aortic valve, includ-
ng inhibition of an Lrp5-mediated cellular proliferation and
ctivation of the osteogenic gene program in the aortic valve
yofibroblast. The other well-known non–lipid-lowering ef-
ect of statins in the vasculature is the improvement in
ndothelial function via modulation of endothelial nitric oxide
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f endothelial nitric oxide synthase enzymatic activity in the
ortic valve of the experimental model of valve atherosclerosis.
he SALTIRE trial was a landmark trial showing that
atients with more a severe degree of aortic stenosis associated
ith a heavily calcified aortic valve would not respond to
igh-dose atorvastatin therapy. Finally, the RAAVE data also
uggest that rosuvastatin has a lipid-lowering effect in slowing
he progression in aortic valvular disease by targeting LDL in
his patient population as compared with the SALTIRE trial.
This was a nonrandomized, prospective, open-label,
bservational study. Therefore, it should be considered
nly hypothesis generating. In this study, patients meet-
ng NCEP-ATPIII guidelines are treated with statins. In
uture randomized blinded trials, the most important ques-
ion to answer is whether those with lower cholesterol with
o indication for statin therapy according to current guide-
ines would derive benefit from statins in terms of aortic
tenosis progression and clinical events such as death or
ortic valve replacement. These results will provide further
upportive evidence for ongoing randomized clinical trials
uch as ASTRONOMER (Aortic Stenosis Progression
bservation Measuring Effects of Rosuvastatin [Canada]),
EAS (Simvastatin and the Ezetimibe in Aortic Stenosis
Europe]) (44), and STOP-AS (Stop Aortic Stenosis
Cleveland Clinic, Cleveland, Ohio]) . The RAAVE study
uggests that earlier treatment with statins is more effica-
ious in the prevention of progression of aortic valve stenosis
han late treatment, similar to the effects of statins in the
egression of vascular atherosclerosis (22).
Importantly, results of the randomized trials will pro-
ide further evidence to define the treatment of this
omplex disease process, in which timing of therapy and
haracteristics of the valve lesion will need to be taken
nto account in the future treatment approaches. In the
AAVE trial, the rate of progression of aortic stenosis in
hose with hypercholesterolemia treated with rosuvasta-
in is slower than in those with lower lipid levels who are
ot treated. This is the first study to provide positive
linical evidence for the potential of targeted therapy in
atients with asymptomatic aortic stenosis.
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